Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment

References

• Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012 Mar 6;109(10):3921–3926.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016 Apr;186(4):733–747.
   PubMed Web of Science ®Google Scholar
• Piek JM, Verheijen RH, Kenemans P, et al. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003 Aug;90(2):491.
   PubMed Web of Science ®Google Scholar
• Mitra AK, Sawada K, Tiwari P, et al. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31;30(13):1566–1576.
   PubMed Web of Science ®Google Scholar
• Ip CK, Yung S, Chan TM, et al. p70 S6 kinase drives ovarian cancer metastasis through multicellular spheroid-peritoneum interaction and P-cadherin/b1 integrin signaling activation. Oncotarget. 2014 Oct 15;5(19):9133–9149.
   PubMed Web of Science ®Google Scholar
• Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006 Nov;7(11):925–934.
   PubMed Web of Science ®Google Scholar
• Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008 Sep;110(3):408–417.
   PubMed Web of Science ®Google Scholar
• Tarin D, Price JE, Kettlewell MG, et al. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 1984 Aug;44(8):3584–3592.
   PubMed Web of Science ®Google Scholar
• Pradeep S, Kim SW, Wu SY, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014 Jul 14;26(1):77–91.
   PubMed Web of Science ®Google Scholar
• Boyd ME. Ovarian cancer. Can J Surg. 1985 Mar;28(2):114–116, 8.
   PubMed Web of Science ®Google Scholar
• Duarte I, Llanos O. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol. 1981 Mar;12(3):237–242.
   PubMed Web of Science ®Google Scholar
• Mao C, Domenico DR, Kim K, et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995 Feb;130(2):125–134.
   PubMedGoogle Scholar
• Carmignani CP, Sugarbaker TA, Bromley CM, et al. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003 Dec;22(4):465–472.
   PubMedGoogle Scholar
• Fujimoto J, Hori M, Ichigo S, et al. Novel screening technique for dissemination potential of ovarian cancer cells to peritoneum. Invasion Metastasis. 1996;16(6):302–307.
   PubMedGoogle Scholar
• Kishikawa T, Sakamoto M, Ino Y, et al. Two distinct patterns of peritoneal involvement shown by in vitro and in vivo ovarian cancer dissemination models. Invasion Metastasis. 1995;15(1–2):11–21.
   PubMedGoogle Scholar
• Iwanicki MP, Davidowitz RA, Ng MR, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov. 2011 Jul;1(2):144–157.
   PubMed Web of Science ®Google Scholar
• Stadlmann S, Feichtinger H, Mikuz G, et al. Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids–evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium. Int J Gynecol Cancer. 2014 Feb;24(2):192–200.
   PubMed Web of Science ®Google Scholar
• Peters PN, Schryver EM, Lengyel E, et al. Modeling the early steps of ovarian cancer dissemination in an organotypic culture of the human peritoneal cavity. J Vis Exp. 2015 Dec;31(106):e53541.
   Google Scholar
• Burleson KM, Boente MP, Pambuccian SE, et al. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 2006 Jan;24(4):6.
   Google Scholar
• Fishman DA, Kearns A, Chilukuri K, et al. Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen. Invasion Metastasis. 1998;18(1):15–26.
   PubMedGoogle Scholar
• Watanabe T, Hashimoto T, Sugino T, et al. Production of IL1-beta by ovarian cancer cells induces mesothelial cell beta1-integrin expression facilitating peritoneal dissemination. J Ovarian Res. 2012 Feb 01;5(1):7.
   PubMed Web of Science ®Google Scholar
• Slack-Davis JK, Atkins KA, Harrer C, et al. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res. 2009 Feb 15;69(4):1469–1476.
   PubMed Web of Science ®Google Scholar
• Rieppi M, Vergani V, Gatto C, et al. Mesothelial cells induce the motility of human ovarian carcinoma cells. Int J Cancer. 1999 Jan 18;80(2):303–307.
   PubMed Web of Science ®Google Scholar
• Akutagawa N, Nishikawa A, Iwasaki M, et al. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model. Jpn J Cancer Res. 2002 Jun;93(6):644–651.
   PubMedGoogle Scholar
• Cannistra SA, Kansas GS, Niloff J, et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993 Aug 15;53(16):3830–3838.
   PubMed Web of Science ®Google Scholar
• Afify AM, Ferguson AW, Davila RM, et al. Expression of CD44S and CD44v5 is more common in stage III than in stage I serous ovarian carcinomas. Appl Immunohistochem Mol Morphol. 2001 Dec;9(4):309–314.
   PubMedGoogle Scholar
• Saga Y, Mizukami H, Suzuki M, et al. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther. 2001 Oct;8(19):1450–1455.
   PubMed Web of Science ®Google Scholar
• Arlt MJ, Novak-Hofer I, Gast D, et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res. 2006 Jan 15;66(2):936–943.
   PubMed Web of Science ®Google Scholar
• Usui A, Ko SY, Barengo N, et al. P-cadherin promotes ovarian cancer dissemination through tumor cell aggregation and tumor-peritoneum interactions. Mol Cancer Res. 2014 Apr;12(4):504–513.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Sedgewick G, Ramakrishnan S. Endostatin binding to ovarian cancer cells inhibits peritoneal attachment and dissemination. Cancer Res. 2007 Nov 15;67(22):10813–10822.
   PubMed Web of Science ®Google Scholar
• Lokman NA, Elder AS, Ween MP, et al. Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget. 2013 Aug;4(8):1199–1211.
   PubMed Web of Science ®Google Scholar
• Kim M, Rooper L, Xie J, et al. Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res. 2012 Jan;10(1):11–24.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Kubushiro K, Ma J, et al. Alteration in the metastatic potential of ovarian cancer cells by transfection of the antisense gene of beta-1,4-galactosyltransferase. Oncol Rep. 2003 Nov-Dec;10(6):1857–1862.
   PubMed Web of Science ®Google Scholar
• Sheets JN, Iwanicki M, Liu JF, et al. SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis. 2016 Oct 24;5(10):e264.
   PubMedGoogle Scholar
• Yeung TL, Leung CS, Yip KP, et al. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015 Oct 01;309(7):C444–C456.
   PubMed Web of Science ®Google Scholar
• Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004 Mar 05;279(10):9190–9198.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr., Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337.
   PubMed Web of Science ®Google Scholar
• O’Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol. 2002 May-Jun;23(3):154–169.
   PubMedGoogle Scholar
• Steentoft C, Vakhrushev SY, Joshi HJ, et al. Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology. EMBO J. 2013 May 15;32(10):1478–1488.
   PubMed Web of Science ®Google Scholar
• Marcos-Silva L, Narimatsu Y, Halim A, et al. Characterization of binding epitopes of CA125 monoclonal antibodies. J Proteome Res. 2014 May 21;13(7), 3349–3359.
   PubMed Web of Science ®Google Scholar
• Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431–457.
   PubMed Web of Science ®Google Scholar
• Das S, Majhi PD, Al-Mugotir MH, et al. Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments. Sci Rep. 2015 Jun 5;05:9759.
   Google Scholar
• Fendrick JL, Konishi I, Geary SM, et al. CA125 phosphorylation is associated with its secretion from the WISH human amnion cell line. Tumour Biol. 1997;18(5):278–289.
   PubMedGoogle Scholar
• Blalock TD, Spurr-Michaud SJ, Tisdale AS, et al. Functions of MUC16 in corneal epithelial cells. Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4509–4518.
   PubMed Web of Science ®Google Scholar
• Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer. 2004 Jan;4(1):45–60.
   PubMed Web of Science ®Google Scholar
• Kabawat SE, Bast RC, Welch WR, et al. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol. 1983 Jan;79(1):98–104.
   PubMed Web of Science ®Google Scholar
• Argueso P, Spurr-Michaud S, Russo CL, et al. MUC16 mucin is expressed by the human ocular surface epithelia and carries the H185 carbohydrate epitope. Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2487–2495.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1–12.
   PubMed Web of Science ®Google Scholar
• Chen K, Gentry-Maharaj A, Burnell M, et al. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J Proteome Res. 2013 Mar 01;12(3):1408–1418.
   PubMed Web of Science ®Google Scholar
• Dharma RT, Park KJ, Smith-Jones P, et al. Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16. Appl Immunohistochem Mol Morphol. 2010 Oct;18(5):462–472.
   PubMedGoogle Scholar
• Pinto R, Carvalho AS, Conze T, et al. Identification of new cancer biomarkers based on aberrant mucin glycoforms by in situ proximity ligation. J Cell Mol Med. 2012 Jul;16(7):1474–1484.
   PubMed Web of Science ®Google Scholar
• Ricardo S, Marcos-Silva L, Pereira D, et al. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Mol Oncol. 2015 Feb;9(2):503–512.
   PubMed Web of Science ®Google Scholar
• Ricardo S, Marcos-Silva L, Valente C, et al. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors. Virchows Arch. 2016 Jun;468(6):715–722.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609–615.
   PubMed Web of Science ®Google Scholar
• Theriault C, Pinard M, Comamala M, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol. 2011 Jun 1;121(3):434–443.
   PubMed Web of Science ®Google Scholar
• Comamala M, Pinard M, Theriault C, et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer. 2011 Mar 15;104(6):989–999.
   PubMed Web of Science ®Google Scholar
• Muniyan S, Haridas D, Chugh S, et al. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Genes Cancer. 2016 Mar;7(3–4):110–124.
   PubMedGoogle Scholar
• Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer. 1992 Feb 01;50(3):373–381.
   PubMed Web of Science ®Google Scholar
• Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A. 1996 Jan 09;93(1):136–140.
   PubMed Web of Science ®Google Scholar
• Kojima T, Oh-Eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995 Sep 15;270(37):21984–21990.
   PubMed Web of Science ®Google Scholar
• Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937–3942.
   PubMed Web of Science ®Google Scholar
• Yamaguchi N, Hattori K, Oh-Eda M, et al. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem. 1994 Jan 14;269(2):805–808.
   PubMed Web of Science ®Google Scholar
• Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer. 2004 May;12(4):19.
   Google Scholar
• Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11531–11536.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chertov O, Zhang J, et al. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res. 2011 Sep 01;71(17):5915–5922.
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1014–1020.
   PubMed Web of Science ®Google Scholar
• Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol. 2003 Nov;27(11):1418–1428.
   PubMed Web of Science ®Google Scholar
• Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001 Dec;7(12):3862–3868.
   PubMed Web of Science ®Google Scholar
• Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005 Dec;124(6):838–845.
   PubMed Web of Science ®Google Scholar
• Huang CY, Cheng WF, Lee CN, et al. Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 2006 Nov-Dec;26(6C):4721–4728.
   PubMed Web of Science ®Google Scholar
• Johnston FM, Tan MC, Tan BR Jr., et al. Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer. Clin Cancer Res. 2009 Nov 01;15(21):6511–6518.
   PubMed Web of Science ®Google Scholar
• Bera TK, Pastan I. Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol. 2000 Apr;20(8):2902–2906.
   PubMed Web of Science ®Google Scholar
• Chang MC, Chen CA, Chen PJ, et al. Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways. Biochem J. 2012 Mar 01;442(2):293–302.
   PubMedGoogle Scholar
• Bharadwaj U, Marin-Muller C, Li M, et al. Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. Carcinogenesis. 2011 Jul;32(7):1013–1024.
   PubMed Web of Science ®Google Scholar
• Zheng C, Jia W, Tang Y, et al. Mesothelin regulates growth and apoptosis in pancreatic cancer cells through p53-dependent and -independent signal pathway. J Exp Clin Cancer Res. 2012 Oct 03;31:84.
   PubMed Web of Science ®Google Scholar
• Wang K, Bodempudi V, Liu ZG, et al. Inhibition of mesothelin as a novel strategy for targeting cancer cells. Plos One. 2012 Apr 2;7(4):e33214.
   PubMed Web of Science ®Google Scholar
• Zhang J, Qiu S, Zhang Y, et al. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res. 2012 Dec;32(12):5151–5158.
   PubMed Web of Science ®Google Scholar
• Kaneko O, Gong L, Zhang J, et al. A binding domain on mesothelin for CA125/MUC16. J Biol Chem. 2009 Feb 06;284(6):3739–3749.
   PubMed Web of Science ®Google Scholar
• Gubbels JA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer. 2006 Oct 26;5(1):50.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Hirono S, Tani M, et al. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 2012 Apr;103(4):739–746.
   PubMed Web of Science ®Google Scholar
• Chen SH, Hung WC, Wang P, et al. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep. 2013;3:1870.
   PubMed Web of Science ®Google Scholar
• Johnson MD, Vito F, Xu H. MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain. Appl Immunohistochem Mol Morphol. 2010 May;18(3):250–253.
   PubMedGoogle Scholar
• Noujaim AA, Schultes BC, Baum RP, et al. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13–evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. Cancer Biother Radiopharm. 2001 Jun;16(3):187–203.
   PubMed Web of Science ®Google Scholar
• Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27(3):418–425.
   PubMed Web of Science ®Google Scholar
• Wagner U, Schlebusch H, Kohler S, et al. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma. 1997 Feb;16(1):33–40.
   PubMedGoogle Scholar
• Sabbatini P, Dupont J, Aghajanian C, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res. 2006 Sep 15;12(18):5503–5510.
   PubMed Web of Science ®Google Scholar
• Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res. 2004 Mar 01;10(5):1580–1587.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Harter P, Scambia G, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO–the MIMOSA study. J Clin Oncol. 2013 Apr 20;31(12):1554–1561.
   PubMed Web of Science ®Google Scholar
• Kline JB, Kennedy RP, Albone E, et al. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-gamma receptor engagement. Oncotarget. 2017 Jul 7;8(32), 52045.
   PubMed Web of Science ®Google Scholar
• Chen Y, Clark S, Wong T, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924–4932.
   PubMed Web of Science ®Google Scholar
• Liu JF, Moore KN, Birrer MJ, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124–2130.
   PubMed Web of Science ®Google Scholar
• Chekmasova AA, Rao TD, Nikhamin Y, et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010 Jul 15;16(14):3594–3606.
   PubMed Web of Science ®Google Scholar
• Koneru M, Purdon TJ, Spriggs D, et al. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015 Mar;4(3):e994446.
   PubMed Web of Science ®Google Scholar
• Marcos-Silva L, Ricardo S, Chen K, et al. A novel monoclonal antibody to a defined peptide epitope in MUC16. Glycobiology. 2015 Nov;25(11):1172–1182.
   PubMed Web of Science ®Google Scholar
• Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007 Sep 01;13(17):5144–5149.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Hassan R, Fitzgerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009 Aug 15;15(16):5274–5279.
   PubMed Web of Science ®Google Scholar
• Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014 Nov 01;120(21):3311–3319.
   PubMed Web of Science ®Google Scholar
• Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010 Dec 15;16(24):6132–6138.
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01;20(23):5927–5936.
   PubMed Web of Science ®Google Scholar
• Le DT, Brockstedt DG, Nir-Paz R, et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res. 2012 Feb 01;18(3):858–868.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325–1333.
   PubMed Web of Science ®Google Scholar
• Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014 Jun;13(6):1537–1548.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014 2;Feb(2):112–120.
   Google Scholar
• Tang Z, Feng M, Gao W, et al. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther. 2013 Apr;12(4):416–426.
   PubMed Web of Science ®Google Scholar
• Bergan L, Gross JA, Nevin B, et al. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Cancer Lett. 2007 Oct 08;255(2):263–274.
   PubMed Web of Science ®Google Scholar
• Su Y, Tatzel K, Wang X, et al. Mesothelin’s minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane. Oncotarget. 2016 May 24;7(21):31534–31549.
   PubMed Web of Science ®Google Scholar
• Spitzer D, McDunn JE, Plambeck-Suess S, et al. A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing. Mol Cancer Ther. 2010 Jul;9(7):2142–2151.
   PubMed Web of Science ®Google Scholar
• Xiang X, Feng M, Felder M, et al. HN125: a novel immunoadhesin targeting MUC16 with potential for cancer therapy. J Cancer. 2011;2:280–291.
   PubMed Web of Science ®Google Scholar
• Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 1997 Jun 15;57(12):2388–2393.
   PubMed Web of Science ®Google Scholar
• Boivin M, Lane D, Piche A, et al. CA125 (MUC16) tumor antigen selectively modulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol. 2009 Dec;115(3):407–413.
   PubMed Web of Science ®Google Scholar